Beranda › Skleroderma › Illinois
Uji klinis Skleroderma di Illinois
11 studi untuk Skleroderma mencari peserta di lokasi di Illinois.
Kota di Illinois
Teks studi resmi (Bahasa Inggris)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Northwestern University, Chicago
- The University of Chicago Medical Center, Chicago
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- University of Illinois Health Outpatient Care Center, Chicago
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06655155A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
Menerima pesertaFase 1
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Chicago
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Menerima pesertaFase 1
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- The University of Chicago Medical Center (UCMC), Chicago
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
Menerima pesertaFase 2/3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Chicago
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chicago
Menerima pesertaFase 1
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT07295847Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Mei 2025 · NCT05892614Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.